Dr. Matthias Eder of the German Cancer Research Center has been working on a new molecule that targets prostate-specific membrane antigen, a protein that clusters on the surface of prostate cancer cells.
The recent controversy over the use of CRISPR-Cas9 tech by a Chinese research group in a failed attempt to reengineer the DNA of a human embryo highlighted the explosive growth of China's discovery work in biotech in general--and gene editing in particular--over the last few years. And with the Chinese government devoting major resources to the development of new labs, outside analysts expect that China will emerge as a major player in gene editing--a prospect that seems to raise fears as wells as fascination. Read more >>
J&J's blockbuster cancer drug Zytiga (abiraterone) has helped redraw the map for treating prostate cancer since its approval four years ago. And now a researcher at the Cleveland Clinic says that a metabolite of the drug may work better than the therapy itself in treating the disease. Cleveland Clinic researcher Nima Sharifi says that Zytiga is converted into varying levels of D4A in both patients as well as mice after they take the drug. Read more >>
POPULAR COMMENT THREADS
Just about a year after Bristol-Myers Squibb and Allied Minds got together to create Allied-Bristol Life Sciences with plans to collaborate on new biotech spinoffs, the joint venture has inlicensed research from Harvard University that may eventually lead to new drugs for fibrotic and autoimmune diseases.
John Herr's lab at the University of Virginia made the cover of the scientific journal Biology of Reproduction with new work on finding a male contraceptive.
Francesc Rabanal, a professor in the Department of Organic Chemistry of the University of Barcelona, has spearheaded work on a new prototype compound that he says shows clear activity against both Gram-negative and Gram-positive bacteria.
Following up on what's billed as the largest epidemiological study ever done on Parkinson's disease, a group of scientists at Aarhus University in Denmark say they have determined that the neurological ailment begins in the gut and then spreads through the body by way of the vagus nerve.
Researchers at Purdue University say they have identified molecules that can shut down a key enzyme needed by the Middle East respiratory syndrome, or MERS, virus.
Investigators will be making the trek to Washington later this month to make the case for a new study that will explore the impact that metformin has on aging. And in the process, they'll be testing regulators' attitudes about an emerging field in drug development.
From Our Sister Sites
Consultants tell Reuters that large Indian companies are heeding the warnings from regulators and investing more in equipment and training. But some small to medium-sized companies are considering whether to pour money into their operations, retreat from high-profit but regulatory-heavy markets like the U.S. and Europe, or cash out.
India's Dr. Reddy's Laboratories is having to recall both an epilepsy drug and a combo cardiovascular drug all made in India. One, the FDA says, is too strong while the other is not strong enough. The recalls come even as the FDA has been paying special attention to generic equivalence after testing has found evidence that some generics are not measuring up.